Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Business Wire July 18, 2023

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

Business Wire May 17, 2023

Harrow Health Investor Alert

Newsfile May 15, 2023

Harrow Health Investor Alert

Newsfile May 12, 2023

Harrow Announces First Quarter 2023 Financial Results

Business Wire May 11, 2023

Harrow Health Shareholder Notice

Newsfile May 10, 2023

Harrow Health Investor Alert

Newsfile May 8, 2023

Harrow Health Shareholder Action Reminder

Newsfile May 5, 2023

Harrow to Launch FDA-Approved IHEEZO(TM) at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Business Wire May 4, 2023

Harrow Health Investor Alert

Newsfile May 3, 2023

Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.

Business Wire May 2, 2023

Harrow Health Shareholder Notice

Newsfile May 1, 2023

Harrow Health Investor Alert

Newsfile April 28, 2023

Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

Business Wire April 27, 2023

Harrow Health Investor Alert

Newsfile April 26, 2023

Harrow Health Shareholder Action Reminder

Newsfile April 24, 2023

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

PR Newswire April 22, 2023

Harrow Health Shareholder Notice

Newsfile April 21, 2023

Harrow Health Shareholder Notice

Newsfile April 19, 2023

Harrow Health Investor Alert

Newsfile April 17, 2023